- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05698979
Evaluation of Botulinum TOXin Type A in the Treatment of Buerger's Disease (BETOX)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Buerger's disease or obliterate thromboangiitis(TAO) is a rare disease. It is an inflammatory, segmental and occlusive disease affecting small and medium caliber arteries and veins in the extremities of the limbs. It mainly affects young men, who traditionally smoke, before the age of 45. There is currently no specific treatment for Buerger's disease. Surgical treatment is rarely feasible, due to distal and diffuse damage. Several studies have evaluated the perivascular injection of botulinum toxin type A (BTX) in patients with severe Raynaud syndromes linked to scleroderma, with promising results.
Studies with BTX have shown reduced pain, improved tissue perfusion with laser doppler, and healing of digital ulcers.
The patients are treated with a single session with botulinum toxin A injections during an hospital visit, and the judgmental criteria are assessed at 1, 3 and 6 months post injections.
The injections are made at 4 injection points at the palmar or distal plantar fold, at the level of the neurovascular beams, 2h after topical anesthesia by lidocaine cream under occlusion, associated or not with nitrous oxide inhaled at the time of the injections (BOTOX® 100 U, botulinum toxin A injections in each hand or foot, for a final dose of 50 U (1 ml) per extremity).
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Julie Malloizel-Delaunay, MD
- Phone Number: 05 61 32 30 33
- Email: malloizel-delaunay.j@chu-toulouse.fr
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years
- patient with Buerger's disease according to Olin criteria (ref)
- with digital ischemia with critical upper or lower limb ischemia criteria defined as Upper limb: pain and/or trophic disorders for at least 15 days AND digital pressure less than 50 mmHg Or TCPO2 30 mmHg) Or/and Lower limb: pain and/or trophic disorders for at least 15 days AND ankle pressure less than 50 mmHg (70 mmHg if diabetes), or 30 mmHg at the toe (50 mmHg if diabetes) or TCPO2 30 mmHg).
- Ability to attend study visits
- Ability to complete daily study agenda
- Ability to give free and informed consent
- Membership of a Social Security scheme
Exclusion Criteria:
- History of myasthenia gravis or Eaton-Lambert syndrome
- History of inflammatory myositis for less than 2 years or pre-existing motor neuron disease or superior limb neuropathy.
- Known allergy to botulinum toxin or cream lidocaine, albumin or inhaled nitrous oxide/oxygen.
- Progressive infection of one hand or foot
- Aminoglycoside treatment
- Pregnant or nursing women
- History of vascular surgery of surgical sympathectomy of upper or lower limb
- Revascularization procedure considered within 3 months of inclusion
- Risk of major amputation within 3 months of inclusion
- Iloprost expected within one month of study treatment
- Hyperbaric chamber sessions scheduled within one month of study treatment
- Life expectancy less than 6 months
- Contraindication to one or more of the following products: BOTOX 100 UNITS ALLERGAN, LIDOCAINE/PRILOCAINE 5%, cream or NITROUS OXIDE MEDICINAL
- Patients treated by class III anti arhythmic drugs for example amiodarone 15 ) Patient with guardians, curators, or protection of justice
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: drug administration
Botox Injection
|
The patient will be treated with a single session with botulinum toxin A injections at the hospital, and the judgmental criteria will be assessed at 1, 3 and 6 months post injections. The injections will be made in 4 injection points at the palmar or distal plantar fold, at the level of the neurovascular beams, 2h after topical anesthesia by lidocaine cream under occlusion, associated or not with nitrous oxide inhaled at the time of the injections (BOTOX® 100 U). In the event of multiple lesions, a single limb is injected based on clinical severity (ulcer, gangrene) and ischemia parameters (lowest TCPO2).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility in Number of patients
Time Frame: through study completion, an average of 18 months
|
The feasibility criterion corresponds to the number of patients who actually received the planned injections within the defined time limits, among the patients who should have received the injection according to the criteria of the protocol.
|
through study completion, an average of 18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
tolerance during injection
Time Frame: during injection
|
collection of temporary high grade adverse events (muscle weakness, temporary or prolonged headache, general muscle weakness or muscle group at distance from injection site, difficulty swallowing, dyspnea, immediate allergic reaction to injections)
|
during injection
|
tolerance after injection
Time Frame: 2 hours after injection
|
collection of temporary high grade adverse events (muscle weakness, temporary or prolonged headache, general muscle weakness or muscle group at distance from injection site, difficulty swallowing, dyspnea, immediate allergic reaction to injections)
|
2 hours after injection
|
tolerance of participants
Time Frame: during injection
|
collection of temporary low grade adverse events (hematoma, erythema, ecchymosis at the injection site, pain, before/after and during injection)
|
during injection
|
tolerance of participants
Time Frame: 2 hours after injection
|
collection of temporary low grade adverse events (hematoma, erythema, ecchymosis at the injection site, pain, before/after and during injection)
|
2 hours after injection
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Julie Malloizel-Delaunay, MD, University Hospital, Toulouse
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Skin Diseases
- Arterial Occlusive Diseases
- Embolism and Thrombosis
- Vasculitis
- Skin Diseases, Vascular
- Thrombosis
- Peripheral Vascular Diseases
- Livedoid Vasculopathy
- Raynaud Disease
- Thromboangiitis Obliterans
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Botulinum Toxins
Other Study ID Numbers
- RC31/20/0445
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Raynaud Syndrome
-
University of Toledo Health Science CampusElectroCore INCTerminatedRaynaud Disease | Raynaud Phenomenon | Primary Raynaud Phenomenon | Raynaud SyndromeUnited States
-
University of MinnesotaWithdrawnRaynaud Disease | Raynaud Phenomenon | Raynaud SyndromeUnited States
-
University of CologneCompleted
-
University of Central FloridaTerminatedRaynaud PhenomenonUnited States
-
University of NottinghamCompleted
-
Universidad de GranadaCompletedRaynaud Disease | Raynaud PhenomenonSpain
-
University Medical Center GroningenRecruiting
-
University Hospital, GrenobleUniversity Hospital, RouenRecruitingRaynaud PhenomenonFrance
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Lawson Health Research InstituteDelivra, Inc.Withdrawn
Clinical Trials on BOTOX INJECTION
-
Hospices Civils de LyonCompletedAmyotrophic Lateral Sclerosis | SialorrheaFrance
-
Assistance Publique Hopitaux De MarseilleUnknownHemiplegic Patients Post-AVCFrance
-
Michael Zell, MDNot yet recruitingOveractive Bladder | Benign Prostatic HyperplasiaUnited States
-
Rebecka OhmRecruitingFacial Palsy | Bell Palsy | Facial Paralysis | Synkinesis | Peripheral Facial Palsy | Peripheral Facial ParalysisSweden
-
Damascus UniversityCompletedNocturnal BruxismSyrian Arab Republic
-
AHMED FARAHAT HASSANUnknown
-
Assiut UniversityUnknown
-
NICHD Pelvic Floor Disorders NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedUrinary Incontinence, Stress | Urinary Incontinence, UrgeUnited States
-
Beni-Suef UniversityCompletedBenign Prostatic HyperplasiaEgypt
-
University of AlbertaWithdrawnHemorrhagic Stroke | Reversible Cerebral Vasoconstriction Syndrome | Cerebral Venous Sinus Thrombosis | Headache, Migraine | Stroke (CVA) or TIA | Botulinum Toxins, Type A | Carotid Dissection Artery | Vertebral Dissection ArteryCanada